First-Line Talazoparib plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Adding talazoparib to standard-of-care enzalutamide significantly improved radiographic progression-free survival.

The prior PROpel trial (NEJM Evid 2022; 1:EVIDoa2200043) demonstrated the efficacy of adding a poly(ADP-ribose) polymerase (PARP) inhibitor (olaparib) to an androgen receptor inhibitor (ARI; abiraterone) in the first-line setting for patients with metastatic castration-resistant prostate cancer (mCRPC). The benefit was achieved irrespective of homologous recombination repair (HRR) gene mutation status, including BRCA1/2, but was greater in HRR-deficient patients. HRR gene alterations are found in approximately 25% of patients and can increase sensitization to PARP inhibitor therapy.

Now, investigators have conducted a similar industry-sponsored, international, randomized, double-blind, placebo-controlled, phase 3 trial (TALAPRO-2) to evaluat…

Reviewing Author

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

Robert Dreicer, MD, MS, MACP, FASCO

Disclosures

Consultant/Advisory BoardAstellas; Aveo; Bayer; Gilead; Merck; Pfizer; Propella; Macrogenics

Editorial BoardsCurrent Urology Reports

First-Line Talazoparib plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

Topics

Reviewing Author